Cluster designation (CD) molecules are cell surface antigens differentially expressed among the various cell types of our body. The major cell types of the prostate can be identified by their CD expression. The CD phenotype for prostate cancer cells is CD10-/CD13-CD24/CD26+/CD38/CD57+/CDw75+/CD107b+, found for many tumors examined. It is like the CD10+/CD13+/CD24+/CD26+/CD38+/CD57+/CDw75+/CD107b+ pattern of luminal cells save for CD10 and CD13, and very unlike the CD10-/CD13-/CD24-/CD26-/CD38+/CD57-/CDw75-/CD107b- pattern of basal cells. Hence, cancer cells differ from their normal counterpart in the absent expression of CD10 and CD13, increased expression of CD24, and diminished or absent expression of CD38. Variant cancer CD phenotypes such as cancer cells scored CD10+ are also found. About 25% of the primary tumors analyzed contain CD10+ cancer cells. And unlike primary tumors, all lymph node metastases analyzed to date have CD10+ cancer cells. Incidentally, node-derived cell line LNCaP and xenograft LuCaP 35 are both CD10+. Prostate tumors can therefore be characterized by their composition of cancer cell types, and accordingly their behavior is governed by these constituent cell types. The presence of certain cancer cell types would indicate a particular disease course (metastasis to lymph nodes, for example). Thus, cancer CD phenotypes can be used to stratify patients into different prognostic groups and to predict clinical outcome more accurately. While there is differential expression of CD molecules among the cancer cell types several CD molecules are found in almost all types, and these molecules can be targeted for cell killing as a means to treat disseminated disease. We propose to define prostate cell type compositions in putative premalignant lesions, primary tumors and metastases. This study has great potential towards better prostate cancer diagnosis and prognosis. An in vitro three-dimensional cell culture system will be used to study the effect of absent CD10 or CD13 expression in prostate epithelial cell differentiation. CD10 and CD13 are both peptidases and are likely involved in the processing of bioactive signaling peptides. Their absence might lead to the aberrant cellular differentiation and development of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Tricoli, James
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Schools of Medicine
United States
Zip Code
Liu, Alvin Y; Pascal, Laura E; Vencio, Ricardo Z et al. (2010) Stromal-epithelial interactions in early neoplasia. Cancer Biomark 9:141-55
Pascal, Laura E; Vencio, Ricardo Z N; Page, Laura S et al. (2009) Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 9:452
Pascal, Laura E; True, Lawrence D; Campbell, David S et al. (2008) Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 9:246
Pascal, Laura E; Deutsch, Eric W; Campbell, David S et al. (2007) The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder. BMC Urol 7:19
Dall'Era, Marc A; Oudes, Asa; Martin, Daniel B et al. (2007) HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate 67:714-21
Dall'Era, Marc A; True, Lawrence D; Siegel, Andrew F et al. (2007) Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 7:3
Oudes, Asa J; Campbell, Dave S; Sorensen, Carrie M et al. (2006) Transcriptomes of human prostate cells. BMC Genomics 7:92
Goo, Young Ah; Goodlett, David R; Pascal, Laura E et al. (2005) Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol 5:17
Oudes, Asa J; Roach, Jared C; Walashek, Laura S et al. (2005) Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 5:86
Liu, Alvin Y; Brubaker, Kristen D; Goo, Young Ah et al. (2004) Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 60:98-108